Final Results and Notice of AGM

Summary by AI BETAClose X

4basebio PLC reported a significant increase in revenue to £1.7 million for the year ended December 31, 2025, up 81% from £0.9 million in 2024, with DNA sales revenue doubling and clinical stage projects contributing £1.1 million. Despite this growth, the company posted a loss of £16.9 million, attributed to planned investments in commercial infrastructure and product development. Cash and cash equivalents stood at £17.8 million at year-end, with subsequent funding providing runway into late 2027. Key operational achievements included obtaining GMP certification, expanding the customer base to over 125, and a 41% increase in new business pipeline value. The company also strengthened its leadership team with new CEO and CFO appointments.

Disclaimer*

Companies

4basebio (4BB)
UK 100

Latest directors dealings